MEET OUR LEADERSHIP TEAM

Nanomab is led by a highly experienced executive team with decades of experience across the pharmaceutical and life science sectors. 

Dr. HH Ting
Dr. HH TingExecutive Chair and Chief Scientific Officer
Dr. Ting is a scientist, entrepreneur and angel investor. He has extensive experience in nuclear medicine and the Chinese healthcare sector. Most recently, he served as CEO and co-founder of Oxford Vacmedix and Biovue Technology Ltd. He was also the co-founder of Genemedix Plc., a biotechnology company once co-listed in main boards of LSE and SSE before its acquisition by the Reliance Group. Earlier in his career, he was the China General Manager of Amersham International Plc. and worked as a consultant for Westinghouse Electric, J&J and GE Healthcare. Dr. Ting received his DPhil degree from the University of Oxford, and held a permanent university senior research staff position under Professor J.E.Baldwin’s group before he left for industry.
Henry HH Ho
Henry HH HoExecutive Director and Financial Controller (Interim)
Mr. Ho has over 30 years of operational, financial and capital market experience in industries that include healthcare & investment banking. Prior to joining NanoMab, he served as the GM of Ningbo JACO Pharmaceutical, and was responsible for its nuclear medicine product line expansion. He also served as director of Tasly Pharmaceutical Group and co-founded Oxford VacMedix. He held senior positions at various financial institutions, including Greater China head at Baring Asset Management Asia, Founder of Atlantis Investment Management Asia and China research head at Morgan Stanley, Merrill Lynch and UBS. He also had experience with publicly listed companies, including directorship at HK companies and CFO of a NASDAQ company. Mr. Ho holds a master’s degree in accounting and finance from Lancaster University, UK and is a fellow member of HKICPA.
Nicholas CL Wong
Nicholas CL Wong Project Director
Nicholas has broad experience in the development of innovative cancer treatments. Prior to joining NanoMab, he held the position of project manager in Jiangsu Laitai Medical Biotech Ltd, responsible for the early development of a liver cancer specific peptide pharmaceutical. He also served as application scientist at Roche Diagnostic where he was in charge of implementing cancer molecular diagnostics in Hong Kong. Nicholas is a founder of Novus Life Sciences Ltd, a Hong Kong Science and Technology Park biotechnology incubator company focusing on the development of novel bone cement formulations. Nicholas received his academic training and PhD in cancer biology from the University of Hong Kong.
Dr. Gitasha Chand
Dr. Gitasha Chand Clinical Research Director
Gitasha has extensive experience in clinical development of radiopharmaceuticals. Prior to NanoMab, she has worked on a phase 2 clinical development of Re-188 HEDP, a radiopharmaceutical for palliative treatment of patients with metastatic bone disease. Earlier in her career, she was a resident trainee physician at Shanghai East Hospital specializing in emergency and disaster medicine. Gitasha holds a MBBS from Tongji University Medical School and a Master’s with Distinction in Nuclear Medicine Science and Practice from King’s College London. She successfully oversaw the completion of NanoMab’s two early phase 1 studies in Shanghai and is now managing NanoMab’s ongoing clinical programmes in London and Europe.
 Dr. Levente Meszaros
Dr. Levente MeszarosSenior Project Manager
Levente has over 10 years of experience in the development of radiopharmaceuticals. Earlier in his career he worked as a research associate and radiation protection supervisor at King’s College London, where his research focused on the development of radiopharmaceuticals targeting osteolytic bone disease and novel tracers for ex vivo cell radiolabeling. Upon leaving King’s College London he worked at BioProbe Ltd as project leader and at Theragnostics Ltd as quality control scientist. Levente holds master’s degrees in chemistry, clinical chemistry and radiopharmaceutics from the University of Szeged, Hungary and King’s College London and a PhD in imaging sciences and radiation biology from King’s College London.
WH Huang
WH Huang Shanghai Nanomab Technology Ltd.
General Manager
Mr. Huang has over 20 years of experience in research, development and commercialization in the Chinese biotechnology sector. Prior to joining NanoMab, he was an associate professor at The Institute of Translational Medicine of Shanghai General Hospital. He also served as the SVP of Cell Signaling Company and R&D director of Shanghai State Biotechnology Co., Ltd. Mr. Huang holds a master’s degree in bioengineering from Fudan University and an MBA from Richmond Business Administration College.